Authorised Prescriber (AP) and Special Access Scheme (SAS) applications for ‘unapproved’ medicinal cannabis products are now made by active ingredient rather than brand name.
Five new categories stratify medicinal cannabis products by cannabinoid content.
Prescribers no longer need to submit a separate application to the Therapeutics Goods Administration (TGA) each time they change the product prescribed. This allows greater flexibility when substituting products within the active ingredient category and dosage form for which approval has been granted.
A published list of medicinal cannabis products is available on the TGA website.
From 28 April 2022, extemporaneous compounding of medicinal cannabis products can only occur with a prescription with AP or SAS approval.
